DE10246890A1
(en)
*
|
2002-10-08 |
2004-04-22 |
Grünenthal GmbH |
New C-(imidazo-(1,2-a)-pyridin-3-yl)-methylamines, are nitrogen monoxide synthase inhibitors useful e.g. for treating migraine, septic shock, neurodegenerative diseases, inflammatory pain or cancer
|
DE10247271A1
(en)
*
|
2002-10-10 |
2004-08-26 |
Grünenthal GmbH |
Use of new and known 7-(methyl or trifluoromethyl)-imidazo-(1,2-a)-pyridines as nitrogen monoxide synthase inhibitors useful e.g. for treating migraine, neurodegenerative diseases, inflammatory pain, diabetes or cancer
|
GB0320806D0
(en)
|
2003-09-05 |
2003-10-08 |
Astrazeneca Ab |
Therapeutic treatment
|
AU2004287847A1
(en)
|
2003-10-28 |
2005-05-19 |
Sepracor Inc. |
Imidazo(1,2-a)pyridine anxiolytics
|
FR2874611B1
(en)
*
|
2004-08-31 |
2006-11-17 |
Servier Lab |
NOVEL IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
AU2006331673B2
(en)
|
2005-12-23 |
2013-02-28 |
Ariad Pharmaceuticals, Inc. |
Bicyclic heteroaryl compounds
|
WO2008027812A2
(en)
|
2006-08-28 |
2008-03-06 |
Forest Laboratories Holdings Limited |
Imidazopyridine and imidazopyrimidine derivatives
|
WO2008032764A1
(en)
|
2006-09-13 |
2008-03-20 |
Kyowa Hakko Kirin Co., Ltd. |
Fused heterocyclic derivative
|
KR20090094336A
(en)
|
2006-11-27 |
2009-09-04 |
하. 룬트벡 아크티에 셀스카브 |
Heteroaryl amide derivatives
|
AR064491A1
(en)
|
2006-12-22 |
2009-04-08 |
Astex Therapeutics Ltd |
IMIDAZO DERIVATIVES [1, 2-A] PYRIMIDINE, A PROCESS FOR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE TREATMENT OF DISEASES MEDIATED BY FGFR KINASES.
|
CA2672213C
(en)
|
2006-12-22 |
2016-02-16 |
Astex Therapeutics Limited |
Bicyclic amine derivatives as protein tyrosine kinase inhibitors
|
EP1974729A1
(en)
*
|
2007-03-28 |
2008-10-01 |
Santhera Pharmaceuticals (Schweiz) AG |
Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
|
MX2009010523A
(en)
|
2007-04-10 |
2009-12-15 |
Lundbeck & Co As H |
Heteroaryl amide analogues as p2x7 antagonists.
|
EP2180893B1
(en)
|
2007-08-09 |
2014-11-12 |
Urifer Ltd |
Pharmaceutical compositions and methods for the treatment of cancer
|
GB0720038D0
(en)
|
2007-10-12 |
2007-11-21 |
Astex Therapeutics Ltd |
New compounds
|
GB0720041D0
(en)
|
2007-10-12 |
2007-11-21 |
Astex Therapeutics Ltd |
New Compounds
|
KR20100091965A
(en)
*
|
2007-10-24 |
2010-08-19 |
니혼 메디피직스 가부시키가이샤 |
Novel compound having affinity for amyloid
|
EP2072516A1
(en)
|
2007-12-21 |
2009-06-24 |
Santhera Pharmaceuticals (Schweiz) AG |
Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists
|
EP2103614A1
(en)
|
2008-03-18 |
2009-09-23 |
Santhera Pharmaceuticals (Schweiz) AG |
Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators
|
GB0810902D0
(en)
|
2008-06-13 |
2008-07-23 |
Astex Therapeutics Ltd |
New compounds
|
EP2168965A1
(en)
*
|
2008-09-25 |
2010-03-31 |
Santhera Pharmaceuticals (Schweiz) AG |
Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
|
GB0906470D0
(en)
|
2009-04-15 |
2009-05-20 |
Astex Therapeutics Ltd |
New compounds
|
GB0906472D0
(en)
|
2009-04-15 |
2009-05-20 |
Astex Therapeutics Ltd |
New compounds
|
ES2486715T3
(en)
|
2009-06-29 |
2014-08-19 |
Incyte Corporation |
Pyrimidinones as PI3K inhibitors
|
EA020847B1
(en)
|
2009-10-30 |
2015-02-27 |
Янссен Фармацевтика Нв |
IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
|
US8759359B2
(en)
|
2009-12-18 |
2014-06-24 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as PI3K inhibitors
|
AR080754A1
(en)
|
2010-03-09 |
2012-05-09 |
Janssen Pharmaceutica Nv |
IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
|
CA2796311A1
(en)
|
2010-04-14 |
2011-10-20 |
Incyte Corporation |
Fused derivatives as pi3k.delta. inhibitors
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
ES2764848T3
(en)
|
2010-12-20 |
2020-06-04 |
Incyte Holdings Corp |
N- (1- (substituted phenyl) ethyl) -9H-purine-6-amines as PI3K inhibitors
|
KR20140048079A
(en)
|
2011-02-01 |
2014-04-23 |
교와 핫꼬 기린 가부시키가이샤 |
Ring-fused heterocyclic derivative
|
US9108984B2
(en)
|
2011-03-14 |
2015-08-18 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
|
US9126948B2
(en)
|
2011-03-25 |
2015-09-08 |
Incyte Holdings Corporation |
Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
|
MX344600B
(en)
|
2011-06-27 |
2016-12-20 |
Janssen Pharmaceutica Nv |
1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES.
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
EP2751109B1
(en)
|
2011-09-02 |
2016-11-30 |
Incyte Holdings Corporation |
Heterocyclylamines as pi3k inhibitors
|
AR090548A1
(en)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
|
JP6426603B2
(en)
|
2012-06-26 |
2018-11-21 |
ヤンセン ファーマシューティカ エヌ.ベー. |
A PDE2 inhibitor such as a 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] -quinoxaline compound and a PDE10 inhibitor for use in the treatment of a neurological or metabolic disorder combination
|
BR112015000459B1
(en)
|
2012-07-09 |
2022-02-08 |
Janssen Pharmaceutica N.V. |
PHOSPHODIESTERASE 10 ENZYME INHIBITORS, THEIR USE, PHARMACEUTICAL COMPOSITION INCLUDING THEM, THEIR PREPARATION PROCESS AND PRODUCT
|
JP6193233B2
(en)
|
2012-07-31 |
2017-09-06 |
協和発酵キリン株式会社 |
Fused heterocyclic compounds
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
EP3262046B1
(en)
|
2015-02-27 |
2020-11-04 |
Incyte Corporation |
Salts of pi3k inhibitor and processes for their preparation
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
EP3386993A1
(en)
|
2015-12-10 |
2018-10-17 |
Bayer Pharma Aktiengesellschaft |
Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same
|
EA201891374A1
(en)
|
2015-12-10 |
2018-11-30 |
Байер Фарма Акциенгезельшафт |
SUBSTITUTED 2-PHENYL-3- (PIPERAZINMETHIL) IMIDAZOPIRIDINES AND THEIR APPLICATION
|
US9926316B2
(en)
*
|
2016-03-03 |
2018-03-27 |
The Cleveland Clinic Foundation |
Antitumor derivatives for differentiation therapy
|
JOP20190005A1
(en)
|
2016-07-20 |
2019-01-20 |
Bayer Ag |
Substituted diazahetero-bicyclic compounds and their use
|
JOP20190284A1
(en)
|
2017-06-14 |
2019-12-11 |
Bayer Pharma AG |
Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
|
CA3073656C
(en)
|
2017-09-22 |
2024-03-05 |
Jubilant Epipad LLC |
Heterocyclic compounds as pad inhibitors
|
DK3697785T3
(en)
|
2017-10-18 |
2023-04-03 |
Jubilant Epipad LLC |
IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS
|
WO2019087214A1
(en)
|
2017-11-06 |
2019-05-09 |
Jubilant Biosys Limited |
Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
|
US11459338B2
(en)
|
2017-11-24 |
2022-10-04 |
Jubilant Episcribe Llc |
Heterocyclic compounds as PRMT5 inhibitors
|
KR20200131845A
(en)
|
2018-03-13 |
2020-11-24 |
주빌런트 프로델 엘엘씨 |
Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
|